Dechra Pharmaceuticals P/E 2024

Dechra Pharmaceuticals Aktienanalyse

What does Dechra Pharmaceuticals do?

Dechra Pharmaceuticals PLC is a British company specializing in animal medicine. It was founded in 1997 and has experienced remarkable growth since then. Dechra is listed on the London Stock Exchange and has its headquarters in Northwich, Cheshire, UK. Dechra builds its business models on a broad portfolio of products and services. The company is primarily focused on the development and sale of pharmaceuticals and diagnostics tailored to the needs of veterinarians and pet owners. The company has an extensive range of animal medicines, divided into categories such as antibiotics, painkillers, and anti-inflammatory drugs. Dechra operates three major business segments that drive its growth: the veterinary medicines business, the diagnostics business, and the specialty pharma business. The veterinary medicines business is the core of Dechra's operations. Here, the company produces products that can be used on livestock and companion animals. Dechra dominates the animal medicine market in Europe and has also established itself in the field of animal health in the US. The diagnostics business is another important segment that focuses on diagnostics and tests to quickly and effectively diagnose animal diseases. These products are primarily sold to veterinarians and veterinary laboratories. Dechra's specialty pharma business focuses on the production of specialty drugs tailored to a specific animal species or a specific disease that affects rarer species. Producing such medications generally requires higher expertise and also results in higher profitability due to typically lower competition. In recent years, Dechra has accelerated its presence and growth through targeted acquisitions. These acquisitions have expanded both Dechra's portfolio and geographic reach. In 2014, Dechra acquired US-based Genera N.A., a specialized pharmaceutical company producing animal medicines. With the acquisition of Genera, Dechra was able to strengthen its presence in the US animal medicine market. The company has also made acquisitions in Europe, such as the acquisition of Eurovet Animal Health in 2020. Eurovet is a Netherlands-based company specializing in animal health products and covers important market regions in Europe. The acquisition of Eurovet has allowed Dechra to strengthen its presence in Germany and Scandinavia. In summary, Dechra Pharmaceuticals PLC is one of the leading companies in the animal medicine industry. The company has maintained its reputation by creating innovative products and services based on the highest manufacturing and operational standards. The company is committed to continuing to provide value to veterinarians and pet owners while improving the health and well-being of animals. Dechra Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/E Details

Deciphering Dechra Pharmaceuticals's P/E Ratio

The Price to Earnings (P/E) Ratio of Dechra Pharmaceuticals is a vital metric that investors and analysts use to determine the company’s market value relative to its earnings. It is calculated by dividing the current stock price by the earnings per share (EPS). A higher P/E ratio could suggest that investors are expecting higher future growth, while a lower ratio may indicate a potentially undervalued company or lower growth expectations.

Year-to-Year Comparison

Assessing Dechra Pharmaceuticals's P/E ratio on a yearly basis provides insights into the valuation trends and investor sentiment. An increasing P/E ratio over the years signifies growing investor confidence and expectations for future earnings growth, while a decreasing ratio may reflect concerns over the company's profitability or growth prospects.

Impact on Investments

The P/E ratio of Dechra Pharmaceuticals is a key consideration for investors aiming to balance risk and reward. A comprehensive analysis of this ratio, in conjunction with other financial indicators, aids investors in making informed decisions regarding buying, holding, or selling the company’s stocks.

Interpreting P/E Ratio Fluctuations

Fluctuations in Dechra Pharmaceuticals’s P/E ratio can be attributed to various factors including changes in earnings, stock price movements, and shifts in investor expectations. Understanding the underlying reasons for these fluctuations is essential for predicting future stock performance and assessing the company's intrinsic value.

Frequently Asked Questions about Dechra Pharmaceuticals stock

What is the price-to-earnings ratio of Dechra Pharmaceuticals?

The price-earnings ratio of Dechra Pharmaceuticals is currently 29.69.

How has the price-earnings ratio of Dechra Pharmaceuticals changed compared to last year?

The price-to-earnings ratio of Dechra Pharmaceuticals has increased by -120.9% fallen (meaning "decreased" or "dropped") compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Dechra Pharmaceuticals high compared to other companies?

Yes, the price-to-earnings ratio of Dechra Pharmaceuticals is high compared to other companies.

How does an increase in the price-earnings ratio of Dechra Pharmaceuticals affect the company?

An increase in the price-earnings ratio of Dechra Pharmaceuticals would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Dechra Pharmaceuticals affect the company?

A decrease in the price-earnings ratio of Dechra Pharmaceuticals would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Dechra Pharmaceuticals?

Some factors that influence the price-earnings ratio of Dechra Pharmaceuticals are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Dechra Pharmaceuticals pay?

Over the past 12 months, Dechra Pharmaceuticals paid a dividend of 0.25 GBP . This corresponds to a dividend yield of about 0.65 %. For the coming 12 months, Dechra Pharmaceuticals is expected to pay a dividend of 0.25 GBP.

What is the dividend yield of Dechra Pharmaceuticals?

The current dividend yield of Dechra Pharmaceuticals is 0.65 %.

When does Dechra Pharmaceuticals pay dividends?

Dechra Pharmaceuticals pays a quarterly dividend. This is distributed in the months of November, April, November, April.

How secure is the dividend of Dechra Pharmaceuticals?

Dechra Pharmaceuticals paid dividends every year for the past 25 years.

What is the dividend of Dechra Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0.25 GBP are expected. This corresponds to a dividend yield of 0.65 %.

In which sector is Dechra Pharmaceuticals located?

Dechra Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Dechra Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Dechra Pharmaceuticals from 4/13/2023 amounting to 0.125 GBP, you needed to have the stock in your portfolio before the ex-date on 3/9/2023.

When did Dechra Pharmaceuticals pay the last dividend?

The last dividend was paid out on 4/13/2023.

What was the dividend of Dechra Pharmaceuticals in the year 2023?

In the year 2023, Dechra Pharmaceuticals distributed 0.449 GBP as dividends.

In which currency does Dechra Pharmaceuticals pay out the dividend?

The dividends of Dechra Pharmaceuticals are distributed in GBP.